Applied Therapeutics, Inc. (APLT) Stock

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. Another key compound, AT-001, is currently undergoing pivotal Phase III clinical trials. This therapy is being evaluated for its efficacy in treating both diabetic cardiomyopathy and diabetic peripheral neuropathy. Beyond its clinical pipeline, the company also maintains an early-stage preclinical portfolio. This includes AT-003, which is being developed for diabetic retinopathy, and AT-104. AT-104 is a PI3K inhibitor specifically designed to target T-Cell Acute Lymphoblastic Leukemia, a rare form of blood cancer. Applied Therapeutics, Inc. was established in 2016 and operates from its headquarters in New York City.

Applied Therapeutics, Inc. is headquartered in US.

Applied Therapeutics, Inc. (APLT) stock trades at $0.10 with a market capitalization of $14.86M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.24, reflecting a net loss over the last twelve months, a negative price-to-book of -26.72, reflecting negative shareholders' equity, price-to-sales of 14.86. Over the past 52 weeks the stock has ranged between $0.09 and $1.50, and currently trades 93.3% below its 52-week high.

On profitability, Applied Therapeutics, Inc. generates a return on equity (ROE) of -348.18% (not meaningful, as shareholders' equity is negative), return on capital employed of -173.33%.

Official website: www.appliedtherapeutics.com

Applied Therapeutics, Inc. by the numbers, 2017–2024

Between 2017 and 2024 Applied Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-106.0M.

On a trailing twelve-month basis to Sep '25, revenue is $1.0M and net profit $-18.0M.

Borrowings stand at $3.0M, cash on hand is $11.9M, cash from operations was $-84.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -367.6% over five years, and was -186.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Applied Therapeutics, Inc. (APLT) — frequently asked questions